Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate cancer cells

Journal of Biological Chemistry

Volumn 291, Issue 34, 2016, Pages 17861-17880

  Misawa, Aya ^a   Takayama, Ken Ichi ^a,b   Urano, Tomohiko ^a   Inoue, Satoshi ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SIGNALING; GENES; GROWTH KINETICS; UROLOGY;

ANDROGEN RECEPTORS; ANDROGEN-DEPENDENT; APOPTOSIS PATHWAYS; EPIGENETIC CONTROL; PROSTATE CANCER CELLS; PROSTATE CANCERS; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTORS;

DISEASES;

ANDROGEN RECEPTOR; BICALUTAMIDE; DOCETAXEL; LONG UNTRANSLATED RNA; ANDROGEN; RNA; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; EPIGENETICS; GENE; GENE CONTROL; GENE EXPRESSION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOCS2AS1 GENE; TNFSF10 GENE; UPREGULATION; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANDROGENS; APOPTOSIS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, LONG NONCODING; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84983048096     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.718536     Document Type: Article

References (59)

1. ENCODE Project Consortium, Birney, E., Stamatoyannopoulos, J. A., Dutta, A., Guigo', R., Gingeras, T. R., Margulies, E. H., Weng, Z., Snyder, M., Dermitzakis, E. T., Thurman, R. E., Kuehn, M. S., Taylor, C. M., Neph, S., Koch, C. M., Asthana, S., et al. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447,799-816.
2. Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., Xue, C., Marinov, G. K., Khatun, J., Williams, B. A., Zaleski, C., et al. (2012) Landscape of transcription in human cells. Nature 489, 101-108.
3. Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., Cabili, M. N., Jaenisch, R., Mikkelsen, T. S., Jacks, T., Hacohen, N., et al. (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227.
4. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39.
5. Scher, H. I., and Sawyers, C. L. (2005) Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261.
6. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S., Manrai, A. K., et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256.
7. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, et al. (2009) Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790.
8. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005.
9. Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., Flaig, T. W., Fle'chon, A., Mainwaring, P., Fleming, M., et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197.
10. Smith, M. R., Cook, R., Lee, K. A., and Nelson, J. B. (2011) Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117, 2077-2085.
11. Waltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., and Visakorpi, T. (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69, 8141-8149.
12. Sun, S., Sprenger, C. C., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., Nelson, P. S., and Plymate, S. R. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730.
13. Pomerantz, M. M., Beckwith, C. A., Regan, M. M., Wyman, S. K., Petrovics, G., Chen, Y., Hawksworth, D. J., Schumacher, F. R., Mucci, L., Penney, K. L., Stampfer, M. J., Chan, J. A., Ardlie, K. G., Fritz, B. R., Parkin, R. K., et al. (2009) Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 69, 5568-5574.
14. Beckedorff, F. C., Ayupe, A. C., Crocci-Souza, R., Amaral, M. S., Nakaya, H. I., Soltys, D. T., Menck, C. F., Reis, E. M., and Verjovski-Almeida, S. (2013) The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 9, e1003705.
15. Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., Cao, X., Jing, X., Wang, X., Siddiqui, J., Wei, J. T., et al. (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29, 742-749.
16. Prensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., Jenkins, R. B., Triche, T. J., Malik, R., Bedenis, R., McGregor, N., et al. (2013) The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45, 1392-1398.
17. Lee, R. S., and Roberts, C. W. (2013) Linking the SWI/SNF complex to prostate cancer. Nat. Genet. 45, 1268-1269.
18. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., Tomsho, L. P., Peters, B. A., Pujara, K., et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873.
19. de Kok, J. B., Verhaegh, G. W., Roelofs, R. W., Hessels, D., Kiemeney, L. A., Aalders, T. W., Swinkels, D. W., and Schalken, J. A. (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695-2698.
20. Tomlins, S. A., Aubin, S. M., Siddiqui, J., Lonigro, R. J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., Penabella, Y., Day, J. R., Varambally, R., Han, B., Wood, D., et al. (2011) Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3, 94ra72.
21. Srikantan, V., Zou, Z., Petrovics, G., Xu, L., Augustus, M., Davis, L., Livezey, J. R., Connell, T., Sesterhenn, I. A., Yoshino, K., Buzard, G. S., Mostofi, F. K., McLeod, D. G., Moul, J. W., and Srivastava, S. (2000) PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 97, 12216-12221.
22. Zhang, A., Zhao, J. C., Kim, J., Fong, K. W., Yang, Y. A., Chakravarti, D., Mo, Y. Y., and Yu, J. (2015) LncRNA HOTAIR enhances the androgenreceptor- mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 13, 209-221.
23. Takayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie-Inoue, K., Ikeda, K., Urano, T., Kawazu, C., Hasegawa, A., Ikeo, K., Gojyobori, T., Ouchi, Y., Hayashizaki, Y., Aburatani, H., and Inoue, S. (2011) Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30, 619-630.
24. Takayama, K., Horie-Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., Homma, Y., Ouchi, Y., Aburatani, H., Hayashizaki, Y., and Inoue, S. (2013) Androgenresponsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 32, 1665-1680.
25. Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., Barnes, I., Bignell, A., Boychenko, V., Hunt, T., Kay, M., et al. (2012) GENCODE: the reference human genome annotation for the ENCODE Project. Genome Res. 22, 1760-1774.
26. Takayama, K., Suzuki, T., Fujimura, T., Urano, T., Takahashi, S., Homma, Y., and Inoue, S. (2014) CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res. 74, 6542-6553.
27. Takayama, K., Misawa, A., Suzuki, T., Takagi, K., Hayashizaki, Y., Fujimura, T., Homma, Y., Takahashi, S., Urano, T., and Inoue, S. (2015) TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat. Commun. 6, 8219.
28. Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., Miyazaki, T., Leonor, N., Taniguchi, T., Fujita, T., Kanakura, Y., et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924.
29. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., Akira, S., and Kishimoto, T. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929.
30. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921.
31. Takayama, K., Horie-Inoue, K., Suzuki, T., Urano, T., Ikeda, K., Fujimura, T., Takahashi, S., Homma, Y., Ouchi, Y., and Inoue, S. (2012) TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol. Endocrinol. 26, 748-761.
32. Huang, da W., Sherman, B. T., and Lempicki, R. A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13.
33. Huang da, W., Sherman, B. T., Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
34. Farooqi, A. A., Bhatti, S., and Ismail, M. (2012) TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame. Cancer Cell Int. 12, 22.
35. Farooqi, A. A., Rana, A., Riaz, A. M., Khan, A., Ali, M., Javed, S., Mukhtar, S., Minhaj, S., Rao, J. R., Rajpoot, J., Amber, R., Javed, F. A., Waqar-Un-Nisa, Khanum, R., and Bhatti, S. (2012) NutriTRAILomics in prostate cancer: time to have two strings to one's bow. Mol. Biol. Rep. 39, 4909-4914.
36. Chen, S., Gulla, S., Cai, C., and Balk, S. P. (2012) Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J. Biol. Chem. 287, 8571-8583.
37. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. (1999) The AF1 and AF2 domains of the androgen receptor interact with distinct regions of.SRC1. Mol. Cell. Biol. 19, 8383-8392.
38. Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., Chinnaiyan, A. M. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 8, 393-406.
39. Metcalf, D., Greenhalgh, C. J., Viney, E., Willson, T. A., Starr, R., Nicola, N. A., Hilton, D. J., Alexander, W. S. (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405, 1069-1073.
40. Greenhalgh, C. J., Metcalf, D., Thaus, A. L., Corbin, J. E., Uren, R., Morgan, P. O., Fabri, L. J., Zhang, J. G., Martin, H. M., Willson, T. A., Billestrup, N., Nicola, N. A., Baca, M., Alexander, W. S., Hilton, D. J. (2002) Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277, 40181-40184.
41. Neil, H., Malabat, C., d'Aubenton-Carafa, Y., Xu, Z., Steinmetz, L. M., Jacquier, A. (2009) Widespread bidirectional promoters are the major source of cryptic transcripts in yeast. Nature 457, 1038-1042.
42. Sigova, A. A., Mullen, A. C., Molinie, B., Gupta, S., Orlando, D. A., Guenther, M. G., Almada, A. E., Lin, C., Sharp, P. A., Giallourakis, C. C., Young, R. A. (2013) Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 110, 2876-2881.
43. Almada, A. E., Wu, X., Kriz, A. J., Burge, C. B., and Sharp, P. A. (2013) Promoter directionality is controlled by U1 snRNP and polyadenylation signals. Nature 499, 360-363.
44. Ntini, E., Järvelin, A. I., Bornholdt, J., Chen, Y., Boyd, M., J'rgensen, M., Andersson, R., Hoof, I., Schein, A., Andersen, P. R., Andersen, P. K., Preker, P., Valen, E., Zhao, X., Pelechano, V., et al. (2013) Polyadenylation site-induced decay of upstream transcripts enforces promoter directionality. Nat. Struct. Mol. Biol. 20, 923-928.
45. Rhee, H. S., and Pugh, B. F. (2012) Genome-wide structure and organization of eukaryotic pre-initiation complexes. Nature 483, 295-301.
46. Marquardt, S., Escalante-Chong, R., Pho, N., Wang, J., Churchman, L. S., Springer, M., and Buratowski, S. (2014) A chromatin-based mechanism for limiting divergent noncoding transcription. Cell 157, 1712-1723.
47. Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818.
48. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997) The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
49. Aytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M. J., Castillo-Martin, M., Zheng, T., Eastham, J. A., Gopalan, A., Pienta, K. J., Shen, M. M., Califano, A., and Abate-Shen, C. (2014) Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638-651.
50. Lefebvre, C., Rajbhandari, P., Alvarez, M. J., Bandaru, P., Lim, W. K., Sato, M., Wang, K., Sumazin, P., Kustagi, M., Bisikirska, B. C., Basso, K., Beltrao, P., Krogan, N., Gautier, J., Dalla-Favera, R., and Califano, A. (2010) A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377.
51. Zhang, N., Wei, P., Gong, A., Chiu, W. T., Lee, H. T., Colman, H., Huang, H., Xue, J., Liu, M., Wang, Y., Sawaya, R., Xie, K., Yung, W. K., Medema, R. H., He, X., and Huang, S. (2011) FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20, 427-442.
52. Arany, I., Muldrow, M., and Tyring, S. K. (2001) Correlation between mRNA levels of IL-6 and TNF- and progression rate in anal squamous epithelial lesions from HIV-positive men. Anticancer Res. 21, 425-428.
53. Schultheis, B., Carapeti-Marootian, M., Hochhaus, A., Weisser, A., Goldman, J. M., and Melo, J. V. (2002) Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99, 1766-1775.
54. Wikman, A., Olsson, I., Shanwellt, A., and Lundahl, J. (2001) Detection by flow cytometry of antibodies against surface and intracellular granulocyte antigens. Scand. J. Clin. Lab. Invest. 61, 307-316.
55. Sutherland, K. D., Lindeman, G. J., Choong, D. Y., Wittlin, S., Brentzell, L., Phillips, W., Campbell, I. G., and , J. E. (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23, 7726-7733.
56. Iglesias-Gato, D., Chuan, Y. C., Wikström, P., Augsten, S., Jiang, N., Niu, Y., Seipel, A., Danneman, D., Vermeij, M., Fernandez-Perez, L., Jenster, G., Egevad, L., Norstedt, G., and Flores-Morales, A. (2014) SOCS2 mediates the cross-talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 35, 24-33.
57. Hoefer, J., Kern, J., Ofer, P., Eder, I. E., Schäfer, G., Dietrich, D., Kristiansen, G., Geley, S., Rainer, J., Gunsilius, E., Klocker, H., Culig, Z., and Puhr, M. (2014) SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr. Relat. Cancer 21, 175-187.
58. Yang, L., Lin, C., Jin, C., Yang, J. C., Tanasa, B., Li, W., Merkurjev, D., Ohgi, K.A.,Meng,D.,Zhang,J.,Evans,C.P.,andRosenfeld,M.G.(2013)lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500, 598-602.
59. Hung, C. L., Wang, L. Y., Yu, Y. L., Chen, H. W., Srivastava, S., Petrovics, G., and Kung, H. J. (2014) A long noncoding RNA connects c-Myc to tumor metabolism. Proc. Natl. Acad. Sci. U.S.A. 111, 18697-18702.